Filing Details

Accession Number:
0001209191-16-107987
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-03-11 19:43:28
Reporting Period:
2016-02-22
Filing Date:
2016-03-11
Accepted Time:
2016-03-11 19:43:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
895051 Casi Pharmaceuticals Inc. CASI Pharmaceutical Preparations (2834) DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
831547 Spectrum Pharmaceuticals Inc 11500 S. Eastern Ave.
Suite 240
Henderson NV 89052
No No Yes No
1619860 Spectrum Pharmaceuticals Cayman, L.p. C/O Spectrum Pharmaceuticals, Inc.
11500 S. Eastern Ave., Suite 240
Henderson NV 89052
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-02-22 1,008,764 $0.01 4,237,391 No 4 P Direct
Common Stock Acquisiton 2016-02-22 680,113 $0.01 2,856,868 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Indirect See footnote
Footnotes
  1. Pursuant to Investment Agreements, dated as of September 17, 2014 (the "Closing Date"), Spectrum Pharmaceuticals, Inc., a Delaware corporation ("Spectrum") and Spectrum Pharmaceuticals Cayman, L.P., an Exempted Limited Partnership organized under the laws of the Cayman Islands ("Spectrum Cayman"), were issued a contingent right to purchase shares of the Issuer's Common Stock, at par value, in order to maintain their respective post-investment equity ownership percentage as of the Closing Date (the "Contingent Right"), in the event Issuer issued securities (subject to a limited exceptions) after the Closing Date. On January 15, 2016, the Issuer consummated the first tranche of a private placement of 8,448,613 shares of Common Stock and 1,689,722 warrants to certain Investors, which triggered the Contingent Right to Spectrum and Spectrum Cayman to purchase, in the aggregate, 1,688,877 shares of Issuer Common Stock. Spectrum and Spectrum Cayman exercised the Contingent Right.
  2. These securities are owned directly by Spectrum Cayman, which is owned 99% by Spectrum and 1% by Spectrum Pharmaceuticals International Holdings, LLC, a Delaware limited liability company. As a result, Spectrum may be deemed to share voting and dispositive power over the reported securities. Spectrum disclaims beneficial ownership in the shares held directly by Spectrum Cayman except to the extent of its pecuniary interest therein.